DRUGS LOADED INTO RED BLOOD CELLS FOR A MORE TOLERABLE CHEMOTHERAPY (Q4193421): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
DRUGS LOADED INTO RED BLOOD CELLS FOR A MORE TOLERABLE CHEMOTHERAPY | |||||||||||||||
| Property / summary | |||||||||||||||
EVERY DAY ABOUT 10 MILLION PEOPLE DIE OF CANCER WORLDWIDE AND 17 MILLION ARE DIAGNOSED WITH THIS DISEASE. ANYONE WHO HAS HAD THE MISFORTUNE TO DEAL WITH IT KNOWS THAT CHEMOTHERAPY, THE MOST WIDESPREAD THERAPEUTIC APPROACH, HAS SIGNIFICANT SIDE EFFECTS, AFFECTING THE QUALITY OF LIFE OF PATIENTS. IN FACT, CHEMOTHERAPY IS USUALLY ADMINISTERED AT THE MAXIMUM TOLERATED CONCENTRATION, ACTING ON BOTH FAST-GROWING CANCER CELLS AND HEALTHY TISSUES, SOMETIMES DOING MORE HARM THAN GOOD. A µERYLO, A START-UP HIGH-TECH FONDATED by a TEAM OF EXPERTIES IN NEW SUMMINISTRATION SYSTEMS, WE WILL DEVELOPED D-LOADER, A TECHNOLOGY TO CURRE THE CANCRE IN RADICAMENTLY NEW MODE, minimising the toxicity of CHEMIOTERAPY. STARTING FROM THE RECENT CLINICAL VALIDATION OF THE ABILITY OF RED BLOOD CELLS TO ACT AS VECTORS FOR THE RELEASE OF DRUGS, WE HAVE MANAGED TO REALISE THE WORLD’S FIRST MICROFLUIDIC DEVICE IN GR (English) | |||||||||||||||
| Property / summary: EVERY DAY ABOUT 10 MILLION PEOPLE DIE OF CANCER WORLDWIDE AND 17 MILLION ARE DIAGNOSED WITH THIS DISEASE. ANYONE WHO HAS HAD THE MISFORTUNE TO DEAL WITH IT KNOWS THAT CHEMOTHERAPY, THE MOST WIDESPREAD THERAPEUTIC APPROACH, HAS SIGNIFICANT SIDE EFFECTS, AFFECTING THE QUALITY OF LIFE OF PATIENTS. IN FACT, CHEMOTHERAPY IS USUALLY ADMINISTERED AT THE MAXIMUM TOLERATED CONCENTRATION, ACTING ON BOTH FAST-GROWING CANCER CELLS AND HEALTHY TISSUES, SOMETIMES DOING MORE HARM THAN GOOD. A µERYLO, A START-UP HIGH-TECH FONDATED by a TEAM OF EXPERTIES IN NEW SUMMINISTRATION SYSTEMS, WE WILL DEVELOPED D-LOADER, A TECHNOLOGY TO CURRE THE CANCRE IN RADICAMENTLY NEW MODE, minimising the toxicity of CHEMIOTERAPY. STARTING FROM THE RECENT CLINICAL VALIDATION OF THE ABILITY OF RED BLOOD CELLS TO ACT AS VECTORS FOR THE RELEASE OF DRUGS, WE HAVE MANAGED TO REALISE THE WORLD’S FIRST MICROFLUIDIC DEVICE IN GR (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: EVERY DAY ABOUT 10 MILLION PEOPLE DIE OF CANCER WORLDWIDE AND 17 MILLION ARE DIAGNOSED WITH THIS DISEASE. ANYONE WHO HAS HAD THE MISFORTUNE TO DEAL WITH IT KNOWS THAT CHEMOTHERAPY, THE MOST WIDESPREAD THERAPEUTIC APPROACH, HAS SIGNIFICANT SIDE EFFECTS, AFFECTING THE QUALITY OF LIFE OF PATIENTS. IN FACT, CHEMOTHERAPY IS USUALLY ADMINISTERED AT THE MAXIMUM TOLERATED CONCENTRATION, ACTING ON BOTH FAST-GROWING CANCER CELLS AND HEALTHY TISSUES, SOMETIMES DOING MORE HARM THAN GOOD. A µERYLO, A START-UP HIGH-TECH FONDATED by a TEAM OF EXPERTIES IN NEW SUMMINISTRATION SYSTEMS, WE WILL DEVELOPED D-LOADER, A TECHNOLOGY TO CURRE THE CANCRE IN RADICAMENTLY NEW MODE, minimising the toxicity of CHEMIOTERAPY. STARTING FROM THE RECENT CLINICAL VALIDATION OF THE ABILITY OF RED BLOOD CELLS TO ACT AS VECTORS FOR THE RELEASE OF DRUGS, WE HAVE MANAGED TO REALISE THE WORLD’S FIRST MICROFLUIDIC DEVICE IN GR (English) / qualifier | |||||||||||||||
point in time: 31 January 2022
| |||||||||||||||
Revision as of 18:50, 31 January 2022
Project Q4193421 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DRUGS LOADED INTO RED BLOOD CELLS FOR A MORE TOLERABLE CHEMOTHERAPY |
Project Q4193421 in Italy |
Statements
15,000.0 Euro
0 references
30,000.0 Euro
0 references
50.0 percent
0 references
MERYLO' SRL
0 references
OGNI GIORNO CIRCA 10 MILIONI DI PERSONE MUOIONO DI CANCRO IN TUTTO IL MONDO E A 17 MILIONI VIENE DIAGNOSTICATA QUESTA MALATTIA. CHIUNQUE ABBIA AVUTO LA SFORTUNA DI AFFRONTARLA SA CHE LA CHEMIOTERAPIA, L'APPROCCIO TERAPEUTICO PIù DIFFUSO, COMPORTA SIGNIFICATIVI EFFETTI COLLATERALI, CHE INCIDONO SULLA QUALITà DELLA VITA DEI PAZIENTI. INFATTI LA CHEMIOTERAPIA VIENE SOLITAMENTE SOMMINISTRATA ALLA MASSIMA CONCENTRAZIONE TOLLERATA, AGENDO SIA SULLE CELLULE TUMORALI A CRESCITA RAPIDA CHE SUI TESSUTI SANI, A VOLTE FACENDO PIù MALE CHE BENE. A µERYLO, UNA START-UP HIGH-TECH FONDATA DA UN TEAM DI ESPERTI IN NUOVI SISTEMI DI SOMMINISTRAZIONE DI FARMACI, ABBIAMO SVILUPPATO D-LOADER, UNA TECNOLOGIA PER CURARE IL CANCRO IN MODO RADICALMENTE NUOVO, MINIMIZZANDO LA TOSSICITà DELLA CHEMIOTERAPIA. PARTENDO DALLA RECENTE VALIDAZIONE CLINICA DELLA CAPACITà DEI GLOBULI ROSSI DI AGIRE COME VETTORI PER IL RILASCIO DI FARMACI, SIAMO RIUSCITI A REALIZZARE IL PRIMO DISPOSITIVO MICROFLUIDICO AL MONDO IN GR (Italian)
0 references
EVERY DAY ABOUT 10 MILLION PEOPLE DIE OF CANCER WORLDWIDE AND 17 MILLION ARE DIAGNOSED WITH THIS DISEASE. ANYONE WHO HAS HAD THE MISFORTUNE TO DEAL WITH IT KNOWS THAT CHEMOTHERAPY, THE MOST WIDESPREAD THERAPEUTIC APPROACH, HAS SIGNIFICANT SIDE EFFECTS, AFFECTING THE QUALITY OF LIFE OF PATIENTS. IN FACT, CHEMOTHERAPY IS USUALLY ADMINISTERED AT THE MAXIMUM TOLERATED CONCENTRATION, ACTING ON BOTH FAST-GROWING CANCER CELLS AND HEALTHY TISSUES, SOMETIMES DOING MORE HARM THAN GOOD. A µERYLO, A START-UP HIGH-TECH FONDATED by a TEAM OF EXPERTIES IN NEW SUMMINISTRATION SYSTEMS, WE WILL DEVELOPED D-LOADER, A TECHNOLOGY TO CURRE THE CANCRE IN RADICAMENTLY NEW MODE, minimising the toxicity of CHEMIOTERAPY. STARTING FROM THE RECENT CLINICAL VALIDATION OF THE ABILITY OF RED BLOOD CELLS TO ACT AS VECTORS FOR THE RELEASE OF DRUGS, WE HAVE MANAGED TO REALISE THE WORLD’S FIRST MICROFLUIDIC DEVICE IN GR (English)
31 January 2022
0 references
VAREDO
0 references